GlassScriptPhysician profile
Brad A Broussard
NPI 1275551509
$17,344.42
in general payments reported to CMS, 2019-2025
42 companies · $4,666 in 2025
The $4,666 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $2,826 · 2021: $3,195 · 2022: $1,536 · 2023: $1,605 · 2024: $1,777 · 2025: $4,666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,297 · Education: $2,600 · Travel and Lodging: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,297.01 |
| Education | $2,599.99 |
| Travel and Lodging | $151.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,048.00 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $3,377.81 | 2019-2025 | Trelegy Ellipta, Nucala |
| Intuitive Surgical, INC. | $2,775.52 | 2024-2025 | |
| Genzyme Corporation | $876.86 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $734.06 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $676.31 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $395.49 | 2020-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $350.78 | 2019-2024 | Yupelri |
| Insmed, INC. | $303.06 | 2019-2025 | Arikayce, Brinsupri |
| Amgen INC. | $302.32 | 2022-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $302.26 | 2022-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $261.81 | 2019-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $244.62 | 2021-2023 | |
| Getinge USA Sales, LLC | $223.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $205.78 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $181.43 | 2019 | |
| United Therapeutics Corporation | $127.12 | 2019-2023 | Tyvaso |
| Gilead Sciences, INC. | $107.51 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $66.75 | 2025 | Winrevair, Zerbaxa |
| Ani Pharmaceuticals, INC. | $60.07 | 2025 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $58.54 | 2021 | |
| Viatris Specialty LLC | $56.95 | 2025 | Yupelri |
| Verona Pharma, INC. | $55.83 | 2025 | Ohtuvayre |
| Allergan, INC. | $46.06 | 2019 | |
| Janssen Pharmaceuticals, INC | $44.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $43.78 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $30.44 | 2021 | |
| Philips North America LLC | $29.96 | 2023 | |
| Paratek Pharmaceuticals, INC. | $28.48 | 2021 | |
| Abbvie INC. | $26.13 | 2023 | Ubrelvy |
| Pulmonx Corporation | $25.46 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Pfizer INC. | $25.21 | 2022 | |
| Liquidia Technologies, INC. | $22.59 | 2025 | Yutrepia |
| Sanofi-Aventis U.S. LLC | $21.87 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.46 | 2019 | |
| Phadia US INC. | $16.70 | 2022 | |
| Livanova USA, INC. | $14.83 | 2020 | |
| Melinta Therapeutics, LLC | $13.00 | 2023 | Rezzayo, Kimyrsa, Vabomere |
| Circassia INC. | $12.51 | 2019 | |
| Ekos Corporation | $11.79 | 2019 | |
| Abiomed | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.